4D Molecular Therapeutics, Inc. (FDMT)Healthcare | Biotechnology | EmeryVille, United States | NasdaqGS
14.67 USD
-0.24
(-1.610%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 14.67 |
Hot Take ↕ | Aug. 22, 2026, 2:53 a.m. EDT
The investment case here is severely compromised by a brutal multi-year decline and deteriorating fundamentals. Despite a recent price bounce and a 'strong buy' analyst recommendation, the underlying business is bleeding value with negative gross margins, negative free cash flow, and a 75% drop in share price over the last four years. The market has correctly identified this as a value trap; the low valuation multiples reflect the reality of a failing operation, not a bargain opportunity. The options market confirms this pessimism, with traders stacking heavy protection against further drops while avoiding any upside bets. While the recent price action shows some life, the structural damage to the balance sheet and the lack of sustainable profitability make this a dangerous hold for any timeframe. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.126305 |
| MSTL | 0.126979 |
| AutoETS | 0.127197 |
| AutoARIMA | 0.131650 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 6.98 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.208 |
| Excess Kurtosis | -0.90 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.62 |
| Revenue per Share | 1.424 |
| Market Cap | 810,432,576 |
| Forward P/E | -3.59 |
| Beta | 2.69 |
| Profit Margins | -194.74% |
| Website | https://www.4dmoleculartherapeutics.com |
As of Aug. 22, 2026, 2:53 a.m. EDT: Speculators are overwhelmingly bearish, positioning massive volume in deep out-of-the-money puts (strikes 5.0 and 9.0) while virtually ignoring calls. Implied volatility is significantly higher for puts than calls, indicating a strong fear of further downside rather than a bullish expectation.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.4283388 |
| Address1 | 5,858 Horton Street |
| Address2 | Suite 455 |
| All Time High | 55.11 |
| All Time Low | 2.235 |
| Ask | 14.44 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,489,050 |
| Average Daily Volume3 Month | 948,172 |
| Average Volume | 948,172 |
| Average Volume10Days | 1,489,050 |
| Beta | 2.69 |
| Bid | 10.75 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 7.383 |
| City | EmeryVille |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.67 |
| Current Ratio | 8.033 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 15.0 |
| Day Low | 14.2 |
| Debt To Equity | 9.62 |
| Display Name | 4D Molecular Therapeutics |
| Earnings Timestamp End | 1,794,340,800 |
| Earnings Timestamp Start | 1,794,340,800 |
| Ebitda | -188,890,000 |
| Ebitda Margins | -2.05297 |
| Enterprise To Ebitda | -2.585 |
| Enterprise To Revenue | 5.307 |
| Enterprise Value | 488,315,584 |
| Eps Current Year | -4.13556 |
| Eps Forward | -4.08667 |
| Eps Trailing Twelve Months | -2.59 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.0346 |
| Fifty Day Average Change | 2.6353998 |
| Fifty Day Average Change Percent | 0.21898524 |
| Fifty Two Week Change Percent | 142.83388 |
| Fifty Two Week High | 16.93 |
| Fifty Two Week High Change | -2.2600002 |
| Fifty Two Week High Change Percent | -0.13349086 |
| Fifty Two Week Low | 5.97 |
| Fifty Two Week Low Change | 8.700001 |
| Fifty Two Week Low Change Percent | 1.4572866 |
| Fifty Two Week Range | 5.97 - 16.93 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,607,697,000,000 |
| Float Shares | 42,436,946 |
| Forward Eps | -4.08667 |
| Forward P E | -3.5897198 |
| Free Cashflow | -90,773,504 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 196 |
| Fullday Change | -0.24 |
| Fullday Change Percent | -1.60966 |
| Fullday Price | 14.67 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | -1.57704 |
| Gross Profits | -145,100,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02933 |
| Held Percent Institutions | 1.0582399 |
| Implied Shares Outstanding | 55,244,211 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-12-11 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | 4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California. |
| Long Name | 4D Molecular Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 810,432,576 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_272879653 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -179,175,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 823,691,186 |
| Number Of Analyst Opinions | 10 |
| Open | 14.85 |
| Operating Cashflow | -156,071,008 |
| Operating Margins | -20.37159 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 510 505 2680 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 14.67 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 14.91 |
| Price Eps Current Year | -3.5472827 |
| Price Hint | 2 |
| Price To Book | 1.9869972 |
| Price To Sales Trailing12 Months | 8.808284 |
| Profit Margins | -1.94739 |
| Quick Ratio | 7.676 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.24 |
| Regular Market Change Percent | -1.60966 |
| Regular Market Day High | 15.0 |
| Regular Market Day Low | 14.2 |
| Regular Market Day Range | 14.2 - 15.0 |
| Regular Market Open | 14.85 |
| Regular Market Previous Close | 14.91 |
| Regular Market Price | 14.67 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,101,306 |
| Return On Assets | -0.25086 |
| Return On Equity | -0.4325 |
| Revenue Growth | 251.067 |
| Revenue Per Share | 1.424 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 55,244,211 |
| Shares Percent Shares Out | 0.2225 |
| Shares Short | 12,289,621 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 11,363,434 |
| Short Name | 4D Molecular Therapeutics, Inc. |
| Short Percent Of Float | 0.255 |
| Short Ratio | 19.82 |
| Source Interval | 15 |
| State | CA |
| Symbol | FDMT |
| Target High Price | 37.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 29.1 |
| Target Median Price | 30.5 |
| Total Cash | 361,334,016 |
| Total Cash Per Share | 6.541 |
| Total Debt | 39,217,000 |
| Total Revenue | 92,008,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.59 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.983925 |
| Two Hundred Day Average Change | 4.686075 |
| Two Hundred Day Average Change Percent | 0.46936202 |
| Type Disp | Equity |
| Volume | 1,101,306 |
| Website | https://www.4dmoleculartherapeutics.com |
| Zip | 94,608 |